FCM
TARA icon

Farallon Capital Management’s Protara Therapeutics TARA Stock Holding History

Farallon Capital Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-425,000
Closed -$7.15M – 151
2020
Q3 		$7.15M Buy
+425,000
New +$9.86M 0.05% 103

Other funds holding TARA

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Farallon Capital Management's TARA Position: Q4 2020 in Review

Farallon Capital Management sold out of Protara Therapeutics (TARA) in Q4 2020, closing a stake of 425,000 shares — an estimated $7.15M sold.

Farallon Capital Management first reported a position in TARA in Q3 2020 and held it in 1 quarter. The position peaked at $7.15M in Q3 2020. 49 funds tracked by Wall St. Rank hold TARA as of Q4 2020.

  • Farallon Capital Management reported no remaining Protara Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Farallon Capital Management sold 425,000 Protara Therapeutics shares in Q4 2020, an estimated $7.15M.
  • Farallon Capital Management first reported a position in Protara Therapeutics in Q3 2020 and held it in 1 quarter.
  • Farallon Capital Management's Protara Therapeutics position peaked at $7.15M in Q3 2020.
  • 49 funds tracked by Wall St. Rank held Protara Therapeutics as of Q4 2020.

Based on Farallon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.